A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

NCT04736394 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG: APL-1202
DRUG: Epirubicin Hydrochloride

Sponsor

Jiangsu Yahong Meditech Co., Ltd aka Asieris